Page 27 - HK-Connect-2020-21-EN-Nov2020-edition (4)
P. 27

Leading capital markets   Premier international banking centre
       v 2 nd  largest international
        banking hub in Asia in terms of
        external positions (end 2020).
       v 78 of the world's 100 top banks
        operate in Hong Kong (end-June 2021).
       v Robust and well-capitalised banking sector
         - Free flow of capital underpinned
          by a rule-based, transparent regulatory
          environment.                                        #DYNAMIC
         - World-class banking regulation
          and supervision in line with
          international standards.
         - Well-capitalised banking system
          with a total capital ratio of about 20%
          (end-March 2021) and liquidity
 v World No.2 for Initial Public Offering (IPO) funds raised in 2020,     coverage ratio of about 150%
 ranked 1 st  seven times in the past 12 years.    (end-March 2021) – well above
          international standards.
 v World No.1 environment for IPO and M&A (mergers and acquisitions)
 activity (Global Transactions Forecast 2020 compiled by Baker McKenzie   v State-of-the-art financial infrastructure
 and Oxford Economics).    - Real-time gross settlement
 th
 v World's 5  largest and Asia's 2 nd  largest stock market      systems enabling safe and efficient
 by market capitalisation (US$6,871 billion end-May 2021).     settlement of interbank transfers in
          Hong Kong dollar, US dollar, Euro and
 v Asia's largest hedge fund hub and Asia's second largest private     Renminbi.
 equity fund centre (mid 2021).    - Faster Payment System
 v World's leading investment hub: the amount of foreign direct     enabling round-the-clock real-time
 investment (FDI) inflows and outflows ranked 3rd and 4th globally, respectively,     fund transfer and payment services
 in 2020 (UNCTAD: World Investment Report 2021).    across different banks and stored
 v World's second-largest hub for biotech companies –      value facilities.
 55 companies listed under the new listing regime in Hong Kong since its
 introduction in 2018, 36 of which are biotech companies. These 55 companies
 account for about 40% of total IPO funds raised in the period,
 with a total market capitalisation of over US$1.5 trillion.






 24                                           HKCONNECT 2021/22  25
   22   23   24   25   26   27   28   29   30   31   32